David Robles LONDON, Sept. 23, 2026 (GLOBE NEWSWIRE) — OAG, the essential intelligence partner transforming global travel, today announced the appointment of David Robles as a non-executive director. The appointment comes at a significant moment in OAG’s evolution. Founded nearly 100 years ago as aviation’s foundational schedule data provider, OAG
Combined offering pairs the Mavenir AI Integrated Platform with Neysa’s AI cloud to give operators, enterprises, and neocloud providers a sovereign, production-ready path to build, deploy, and monetize AI RICHARDSON, Texas and MUMBAI, India, Sept. 22, 2026 (GLOBE NEWSWIRE) — Mavenir, the cloud-native network software provider building the future of
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Baidu, Inc. (NASDAQ: BIDU) between November 18, 2025 and August 17, 2026, inclusive (the “Class Period”). A class action lawsuit
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Alibaba Group Holding Limited (NYSE: BABA) between June 26, 2025 and June 24, 2026, both dates inclusive (the “Class Period”), of the important October 5, 2026 lead
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Datavault AI Inc. (NASDAQ: DVLT) between September 4, 2024 and October 30, 2025, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline. SO
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark’s February 13, 2025
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline. SO